The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright©ERS Journals Ltd 2008.

Cazzola, M., Macnee, W., Martinez, F.j., Rabe, K.f., Franciosi, L.g., Barnes, P.j., et al. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. EUROPEAN RESPIRATORY JOURNAL, 31(2), 416-468 [10.1183/​09031936.00099306].

Outcomes for COPD pharmacological trials: From lung function to biomarkers

CAZZOLA, MARIO;
2008-01-01

Abstract

The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright©ERS Journals Ltd 2008.
2008
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/10 - MALATTIE DELL'APPARATO RESPIRATORIO
English
Con Impact Factor ISI
bronchodilating agent; carbon monoxide; corticosteroid; hydrocarbon; nitric oxide; biological marker; blood analysis; body weight; bronchus biopsy; cause of death; chronic obstructive lung disease; cost effectiveness analysis; cost of illness; disease course; disease exacerbation; disease marker; disease severity; dyspnea; exercise test; expired air; forced expiratory volume; gas exchange; health status; health survey; human; inflammatory cell; lung function; lung parenchyma; lung volume; mortality; muscle function; priority journal; quality of life; quantitative analysis; rating scale; respiratory failure; review; sputum analysis; treatment outcome; advisory committee; blood; clinical trial; female; lung function test; male; medical society; practice guideline; prognosis; risk assessment; survival; Adrenal Cortex Hormones; Advisory Committees; Biological Markers; Bronchodilator Agents; Clinical Trials as Topic; Female; Humans; Male; Practice Guidelines as Topic; Prognosis; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Risk Assessment; Societies, Medical; Survival Analysis; Treatment Outcome
Cazzola, M., Macnee, W., Martinez, F.j., Rabe, K.f., Franciosi, L.g., Barnes, P.j., et al. (2008). Outcomes for COPD pharmacological trials: From lung function to biomarkers. EUROPEAN RESPIRATORY JOURNAL, 31(2), 416-468 [10.1183/​09031936.00099306].
Cazzola, M; Macnee, W; Martinez, Fj; Rabe, Kf; Franciosi, Lg; Barnes, Pj; Brusasco, V; Burge, Ps; Calverley, Pma; Celli, Br; Jones, Pw; Mahler, Da; Ma...espandi
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/42156
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact